Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324146556> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4324146556 abstract "Pemphigus is a rare group of autoimmune mucocutaneous blistering conditions for which the mainstay of treatment is immunosuppression. This is usually achieved with high dose corticosteroids as well as steroid sparing agents. Rituximab is now recommended as a first line treatment for moderate to severe pemphigus vulgaris, the commonest form of pemphigus, alongside corticosteroids. During the early stages of the COVID-19 pandemic the use of rituximab was reduced in our department due to its long term irreversible B-cell suppression. During the COVID-19 pandemic careful pharmacological selection was undertaken for our pemphigus patients to balance the risks of immunosuppression. To demonstrate this, we report three pemphigus patients who required treatment for COVID-19 and assessment throughout the pandemic. To date there has been limited published data regarding the clinical outcomes of pemphigus patients who have developed COVID-19 infections following rituximab infusions, especially in those patients who have received COVID-19 vaccinations. Following careful personalized consideration, all three pemphigus patients presented received rituximab infusions since the start of the COVID-19 pandemic. These patients had also received COVID-19 vaccinations prior to becoming infected with COVID-19. Each patient had a mild COVID-19 infection after receiving rituximab. We advocate for all pemphigus patients to have a full course of COVID-19 vaccinations. Antibody response to COVID-19 vaccinations should ideally be confirmed by measuring pemphigus patient’s SARS-CoV-2 antibodies prior to receiving rituximab." @default.
- W4324146556 created "2023-03-15" @default.
- W4324146556 creator A5000758369 @default.
- W4324146556 creator A5019467530 @default.
- W4324146556 creator A5083618530 @default.
- W4324146556 date "2023-03-14" @default.
- W4324146556 modified "2023-09-29" @default.
- W4324146556 title "Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia" @default.
- W4324146556 cites W2602517913 @default.
- W4324146556 cites W3015579738 @default.
- W4324146556 cites W3020496963 @default.
- W4324146556 cites W3080818382 @default.
- W4324146556 cites W3091936244 @default.
- W4324146556 cites W3111462670 @default.
- W4324146556 cites W3118121151 @default.
- W4324146556 cites W3123123295 @default.
- W4324146556 cites W3124810175 @default.
- W4324146556 cites W3211083144 @default.
- W4324146556 cites W4206619760 @default.
- W4324146556 cites W4210972925 @default.
- W4324146556 cites W4317423635 @default.
- W4324146556 doi "https://doi.org/10.3389/fmed.2023.1149742" @default.
- W4324146556 hasPublicationYear "2023" @default.
- W4324146556 type Work @default.
- W4324146556 citedByCount "0" @default.
- W4324146556 crossrefType "journal-article" @default.
- W4324146556 hasAuthorship W4324146556A5000758369 @default.
- W4324146556 hasAuthorship W4324146556A5019467530 @default.
- W4324146556 hasAuthorship W4324146556A5083618530 @default.
- W4324146556 hasBestOaLocation W43241465561 @default.
- W4324146556 hasConcept C126322002 @default.
- W4324146556 hasConcept C156662089 @default.
- W4324146556 hasConcept C159654299 @default.
- W4324146556 hasConcept C203014093 @default.
- W4324146556 hasConcept C2779134260 @default.
- W4324146556 hasConcept C2780252810 @default.
- W4324146556 hasConcept C2780653079 @default.
- W4324146556 hasConcept C2781313415 @default.
- W4324146556 hasConcept C2781327288 @default.
- W4324146556 hasConcept C3008058167 @default.
- W4324146556 hasConcept C524204448 @default.
- W4324146556 hasConcept C71924100 @default.
- W4324146556 hasConcept C89623803 @default.
- W4324146556 hasConceptScore W4324146556C126322002 @default.
- W4324146556 hasConceptScore W4324146556C156662089 @default.
- W4324146556 hasConceptScore W4324146556C159654299 @default.
- W4324146556 hasConceptScore W4324146556C203014093 @default.
- W4324146556 hasConceptScore W4324146556C2779134260 @default.
- W4324146556 hasConceptScore W4324146556C2780252810 @default.
- W4324146556 hasConceptScore W4324146556C2780653079 @default.
- W4324146556 hasConceptScore W4324146556C2781313415 @default.
- W4324146556 hasConceptScore W4324146556C2781327288 @default.
- W4324146556 hasConceptScore W4324146556C3008058167 @default.
- W4324146556 hasConceptScore W4324146556C524204448 @default.
- W4324146556 hasConceptScore W4324146556C71924100 @default.
- W4324146556 hasConceptScore W4324146556C89623803 @default.
- W4324146556 hasFunder F4320323121 @default.
- W4324146556 hasLocation W43241465561 @default.
- W4324146556 hasLocation W43241465562 @default.
- W4324146556 hasOpenAccess W4324146556 @default.
- W4324146556 hasPrimaryLocation W43241465561 @default.
- W4324146556 hasRelatedWork W2048084853 @default.
- W4324146556 hasRelatedWork W2128287485 @default.
- W4324146556 hasRelatedWork W2410078214 @default.
- W4324146556 hasRelatedWork W2560649336 @default.
- W4324146556 hasRelatedWork W2913339051 @default.
- W4324146556 hasRelatedWork W3039437100 @default.
- W4324146556 hasRelatedWork W3164467429 @default.
- W4324146556 hasRelatedWork W3192241387 @default.
- W4324146556 hasRelatedWork W4297723280 @default.
- W4324146556 hasRelatedWork W3095051261 @default.
- W4324146556 hasVolume "10" @default.
- W4324146556 isParatext "false" @default.
- W4324146556 isRetracted "false" @default.
- W4324146556 workType "article" @default.